

LABORATORY CORP OF AMERICA HOLDINGS  
Form 8-K  
December 03, 2013

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

December 3, 2013  
(Date of earliest event reported)

LABORATORY CORPORATION OF  
AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)

|  |                          |  |
|--|--------------------------|--|
| Delaware   | 1-11353                  | 13-3757370   |
| (State or other jurisdiction of<br>Incorporation)    | (Commission File Number) | (I.R.S. Employer Identification<br>No.)                |
| 358 South Main Street,<br>Burlington, North Carolina | 27215                    | 336-229-1127   |
| (Address of principal executive offices)             | (Zip Code)               | (Registrant's telephone number<br>including area code) |

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On December 3, 2013, Laboratory Corporation of America<sup>®</sup> Holdings (LabCorp<sup>®</sup>) (NYSE: LH) announced the immediate availability of an enhanced version of its HCV GenoSure<sup>®</sup> NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO<sup>™</sup> (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1 chronic hepatitis C (HCV).

Exhibits

99.1 Press Release dated December 3, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

Registrant

By: /s/ F. SAMUEL EBERTS III  
F. Samuel Eberts III  
Chief Legal Officer and Secretary

December 3, 2013